EUCTR2018-002966-37-BE进行中（未招募）1 期
Efficacy of Olaparib in advanced cancers occurring in patients with germline mutations or somatic tumor mutations in homologous recombination genes. - Precision 2 - Olaparib
Belgian Society of Medical Oncology0 个研究点目标入组 513 人开始时间: 2019年3月6日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 513
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1- Provision of informed consent prior to any study specific procedures
- •2- Female or male aged > 18 years
- •3- Histologically proven advanced cancer, either locally or metastatic, harboring a specific pathogenic genetic alteration (with the exception of breast, pancreas, ovarian or prostate cancer patients harboring a BRCA1/2 mutation)
- •4- No approved targeted therapy for the specific genetic alteration in the specific tumor type
- •5- No other genomic driven phase I, II or III trial available for the specific genomic alteration in the specific tumor type
- •6- Available tumor tissue for verification of the mutation by Sanger sequencing.
- •7- Patients must have normal organ and bone marrow function measured within 28 days prior to administration of study treatment.
- •8- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- •9- Patients must have a life expectancy =16 weeks
- •10- Postmenopausal or evidence of non-childbearing status for women of childbearing potential: negative urine or serum pregnancy test within 28 days of study treatment and confirmed prior to treatment on day 1.
- •11- Patients are willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations.
- •12- At least one lesion (measurable and/or non-measurable) that can be accurately assessed at baseline by CT and is suitable for repeated assessment.
- •13- *Formalin fixed, paraffin embedded (FFPE) tumour sample from the primary cancer must be available for central testing.
- •14- For patients not entering the trial after identification of a genetic alteration in the Precision 1 trial, 2 samples of 10 ml EDTA tubes should be taken to make germ-line DNA analysis possible.
- •15- A new biopsy of tumor tissue with consent of the patient at the moment of progressive disease is preferable
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 342
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 171
排除标准
- •1- Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)
- •2- Ovarian cancer patients harboring a HRD and breast, prostate and pancreas cancer patients who carry a BRCA1/2 mutation
- •3- Previous enrolment in the present study
- •4- Participation in another clinical study with an investigational product during the last 4 weeks or radiotherapy (except for palliative reasons) within three weeks prior to study treatment.
- •5- History of non-compliance to medical regimens
- •6- Any previous treatment with PARP inhibitor, including olaparib.
- •7- Other malignancy within the last 5 years except: adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, ductal carcinoma in situ (DCIS), Stage 1, grade 1 endometrial carcinoma, or other solid tumours including lymphomas (without bone marrow involvement) curatively treated with no evidence of disease for =5 years. Patients with a history of localized triple negative breast cancer may be eligible, provided they completed their adjuvant chemotherapy more than three years prior to registration, and that the patient remains free of recurrent or metastatic disease
- •8- Resting ECG with QTc > 470 msec on 2 or more time points within a 24 hour period or indicating uncontrolled, potentially reversible cardiac conditions as judged by the investigator (er., unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, QTcF prolongation >500ms, electrolyte disturbances, etc.) or patients with congenital long QT syndrome
- •9- Patients receiving any systemic chemotherapy or radiotherapy (except for palliative reasons) within four weeks prior to study treatment. Patients must have recovered from radiotherapy toxicities prior to enrollment.
- •10- Concomitant use of known strong CYP3A inhibitors (eg. itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir orcobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate CYP3A inhibitors (eg. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil). The required washout period prior to starting olaparib is 2 weeks.
- •11- Concomitant use of known strong (eg. phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John’s Wort ) or moderate CYP3A inducers (eg. bosentan, efavirenz, modafinil). The required washout period prior to starting olaparib is 5 weeks for enzalutamide or phenobarbital and 3 weeks for other agents.
- •12- Persistent toxicities (Common Terminology Criteria for Adverse Event (CTCAE) > grade 2) caused by previous cancer therapy, excluding alopecia
- •13- Patients with myelodysplastic syndrome/acute myeloid leukaemia or with features suggestive of MDS/AML.
- •14- Patients with symptomatic uncontrolled brain metastases. A scan to confirm the absence of brain metastases is not required. The patient can receive a stable dose of corticosteroids before and during the study as long as these were started at least 4 weeks prior to treatment. Patients with spinal cord compression unless considered to have received definitive treatment for this and evidence of clinically stable disease for 28 days.
研究者
相似试验
进行中（未招募）
2 期
Efficacy of Olaparib in Advanced Cancers Occurring in Patients With Germline Mutations or Somatic Tumor Mutations in Homologous Recombination GenesAdvanced Cancers Harbouring Mutations in HRGNCT03967938AZ-VUB540
招募中
Unknown
Efficacy and safety of Olaparib treatment for advanced or recurrent breast cancer (OPTIMAL study)JPRN-UMIN000050600Japan Breast Cancer Research Group155
已完成
2 期
Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation PatsOvarianBreastProstatePancreaticAdvanced TumoursNCT01078662AstraZeneca298
已完成
1 期
Phase 1 trial of olaparib with temozolomide in relapsed glioblastomaCancerISRCTN47380065Cancer Research UK45
进行中（未招募）
1 期
Trial comparing weekly chemotherapy with oral olaparib or olaparib and cediranib in women with relapsed ovarian cancer.BRCA mutated platinum-resistant ovarian cancerMedDRA version: 21.1Level: LLTClassification code 10033131Term: Ovarian carcinomaSystem Organ Class: 100000004864EUCTR2016-000559-28-GBniversity of Oxford138